Document is current
Any future updates will be listed below
-
Authors
Magbanua, Mark Jesus M. https://orcid.org/0000-0003-2113-3593
Manon, Nayelis A.
Wolf, Denise M.
Rivero-Hinojosa, Samuel https://orcid.org/0000-0002-3595-8273
Ahmed, Ziad
Sayaman, Rosalyn W. https://orcid.org/0000-0003-1343-0619
Tin, Antony
Renner, Derrick
Kalashnikova, Ekaterina
Brown-Swigart, Lamorna https://orcid.org/0000-0003-2076-5177
Hirst, Gillian L. https://orcid.org/0000-0002-4502-0035
Yau, Christina https://orcid.org/0000-0002-1937-0859
Li, Wen https://orcid.org/0000-0001-6584-363X
Isaacs, Claudine https://orcid.org/0000-0002-9646-1260
Shatsky, Rebecca A.
Clark, Amy S. https://orcid.org/0000-0002-3685-6535
Zimmer, Alexandra https://orcid.org/0000-0001-6789-0982
Delson, Amy L.
Rodriguez, Angel
Liu, Minetta C. https://orcid.org/0000-0002-8206-5232
Pohlmann, Paula R. https://orcid.org/0000-0001-7914-5162
Esserman, Laura J. https://orcid.org/0000-0001-9202-4568
Rugo, Hope S. https://orcid.org/0000-0001-6710-4814
DeMichele, Angela https://orcid.org/0000-0003-1297-4251
van ‘t Veer, Laura https://orcid.org/0000-0002-9838-8298
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA255442, P01CA210961)
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 15 October 2025
First Online: 9 December 2025
Competing interests
: S.R.H., A.T., D.R., E.K., A.R. and M.C.L. are employees of Natera. GLH reports institutional research grant from NIH (1R01CA255442). C.Y. reports institutional research grant from NCI/NIH; salary support and travel reimbursement from Quantum Leap Healthcare Collaborative; US patent titled, “Breast cancer response prediction subtypes,” (No. 18/174,491); and University of California Inventor Share. C.I. reports institutional research funding from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, BMS, Genentech and Novartis; consultancy roles with Arvinas, AstraZeneca, Genentech, Novartis, Pfizer, Gilead, Merck and Seattle Genetics; and royalties from Wolters Kluwer and McGraw Hill. R.A.S. reports institutional research funding from OBI Pharma, Quantum Leap Healthcare, AstraZeneca and Gilead; serves on AstraZeneca and Stemline advisory boards and Gilead speaker’s bureau; and has a consultancy role with Quantum Leap Healthcare. A.S.C. reports institutional research funding from Novartis and Lilly. A.Z. reports institutional research funding from Merck; honoraria for Medscape; participation on Pfizer Advisory Board. P.R.P. reports institutional research funding from Genentech/Roche, Fabre-Kramer, Advanced Cancer Therapeutics, Caris Centers of Excellence, Pfizer, Pieris Pharmaceuticals, Cascadian Therapeutics, BOLT, Byondis, Seagen, Orum Therapeutics, Carisma Therapeutics; consulting fees from Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, HERON, Puma Biotechnology, Sirtex, CARIS Lifesciences, Juniper, Bolt Biotherapeutics, Abbvie; honoraria from Dava Oncology, OncLive/MJH Life Sciences, Frontiers - Publisher, SABCS, ASCO; Speakers’ Bureau: Genentech/Roche (past); patents United States Patent no. 8,486,413, United States Patent no. 8,501,417, United States Patent no. 9,023,362, United States Patent no. 9,745,377; uncompensated roles with Pfizer, Seagen and Jazz. L.J.E. reports funding from Merck & Co.; participation on an advisory board for Blue Cross Blue Shield; and personal fees from UpToDate; unpaid board member of Quantum Leap Healthcare. H.S.R. reports institutional research support from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly; Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambrx, Greenwich Pharma; advisory and consulting roles with Chugai, Puma, Sanofi, Napo, and Helsinn. A.D.M. reports institutional research funding from Novartis, Pfizer, Genentech and Neogenomics; Program Chair, Scientific Advisory Committee, ASCO. L.J.v.V. is an advisor and shareholder of Exai Bio; part-time employee and owns stock in Agendia. All other authors declare no competing interests.
